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1Primary aldosteronism (PA) is a frequent cause of secondary hypertension with a reported prevalence of 5% to 10% in 
unselected populations and up to 20% in patients with resis-
tant hypertension.1–5 The excess aldosterone production that 
causes the disorder may be unilateral (confined to one adrenal) 
or bilateral and the 2 forms are preferentially treated by unilat-
eral adrenalectomy or a mineralocorticoid receptor antagonist, 
respectively.6,7 Unilateral PA is the most common surgically 
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Abstract—Unilateral primary aldosteronism is the most common surgically correctable form of endocrine hypertension 
and is usually differentiated from bilateral forms by adrenal venous sampling (AVS) or computed tomography (CT). 
Our objective was to compare clinical and biochemical postsurgical outcomes of patients with unilateral primary 
aldosteronism diagnosed by CT or AVS and identify predictors of surgical outcomes. Patient data were obtained from 18 
internationally distributed centers and retrospectively analyzed for clinical and biochemical outcomes of adrenalectomy 
of patients with surgical management based on CT (n=235 patients, diagnosed from 1994–2016) or AVS (526 patients, 
diagnosed from 1994–2015) using the standardized PASO (Primary Aldosteronism Surgical Outcome) criteria. 
Biochemical outcomes were highly different according to surgical management approach with a smaller proportion in 
the CT group achieving complete biochemical success (188 of 235 [80%] patients versus 491 of 526 [93%], P<0.001) 
and a greater proportion with absent biochemical success (29 of 235 [12%] versus 10 of 526 [2%], P<0.001). A diagnosis 
by CT was associated with a decreased likelihood of complete biochemical success compared with AVS (odds ratio, 
0.28; 0.16–0.50; P<0.001). Clinical outcomes were not significantly different, but the absence of a postsurgical elevated 
aldosterone-to-renin ratio was a strong marker of complete clinical success (odds ratio, 14.81; 1.76–124.53; P=0.013) 
in the CT but not in the AVS group. In conclusion, patients diagnosed by CT have a decreased likelihood of achieving 
complete biochemical success compared with a diagnosis by AVS.  
Primary Aldosteronism
2correctable cause of hypertension with a highly variable pro-
portion of patients achieving clinical remission after surgery 
between centers.8–10
Patients with PA have a widely reported increased risk of 
prevalent cardiovascular and cerebrovascular complications and 
target organ damage relative to matched patients with primary 
hypertension who have otherwise similar cardiovascular risk 
profiles or compared with the general population with hyper-
tension.11–17 An increasing body of evidence implies that early 
diagnosis and targeted treatment can minimize or reverse the 
increased risks associated with this condition. Failure to identify 
those with unilateral forms constrains patients with unilateral 
disease to a lifetime of medical treatment instead of offering a 
potential surgical cure and has an impact on quality of life.18–21
The accurate differentiation of unilateral from bilateral PA 
is therefore mandatory for optimal clinical management and 
is widely undertaken by adrenal venous sampling (AVS) or 
an imaging technique, usually adrenal computed tomography 
(CT) or magnetic resonance. AVS determines whether one or 
both adrenals are responsible for aldosterone excess. The ability 
of AVS to provide functional information about the source of 
aldosterone overproduction in PA might be expected to render 
it superior in terms of diagnostic accuracy than imaging tech-
niques such as CT which provide only structural information. 
Indeed, CT has been widely reported to be unreliable for differ-
entiation of unilateral from bilateral PA, lacks sensitivity for the 
detection of microadenomas (<10 mm diameter) and specificity 
in patients with nonfunctional adrenal incidentalomas.6,22–27 For 
these reasons, AVS is recommended for the diagnostic workup 
of PA by the clinical practice guideline of the Endocrine Society.6 
The only randomized prospective clinical trial that compared 
AVS and CT in the differentiation of unilateral from bilateral PA 
found no significant differences in clinical outcomes between 
the 2 approaches. A nonsignificant difference in biochemical 
outcomes (80% biochemical remission in the CT versus 89% 
in the AVS group) and health-related quality of life was also 
reported, and the study concluded that the reference standard 
status of AVS in the diagnostic workup of PA was unjustified.28
Our objective was to evaluate the diagnostic value of CT 
compared with AVS for unilateral PA in a large international 
cohort of patients retrospectively assessed for clinical and 
biochemical outcomes by the international PASO (Primary 
Aldosteronism Surgical Outcome) consensus10 and to identify 
predictors of outcomes.
Methods
The authors declare that all supporting data are available within the 
article and in the online-only Data Supplement.
An expanded Methods section is available in the online-only Data 
Supplement.
Patient Cohorts and Outcome Assessment
All 12 centers from the PASO study were invited to contribute patient 
data based on AVS surgical management, of which 9 accepted (Berlin, 
Brisbane, Kyoto, Ljubljana, Munich, Sendai, Torino, Warsaw, and 
Yokohama). Data from 761 patients with unilateral PA were obtained 
(235 with CT management diagnosed from 1994–2016, and 526 with 
AVS management diagnosed from 1994–2015; Table S1 and Figure 
S1 in the online-only Data Supplement). The patients in the AVS 
group are a subset of the patients from the PASO study with the addi-
tion of CT data and 4 extra patients (2 in Munich and 2 in Berlin) 
because of newly available outcome data. The CT group included all 
patients in each center with a diagnosis of unilateral PA by CT in 
the study period (Figure S1). In this group, unilateral PA was diag-
nosed if a unilateral nodule of at least 8 mm in diameter was detected. 
Clinical and biochemical outcomes were assessed retrospectively in 
accordance with the standardized criteria of the PASO consensus 
with follow-up at 6 to 12 months which are based on blood pres-
sure measurements and antihypertensive drug dosage (clinical out-
comes) and assessment of the aldosterone-to-renin ratio (ARR) and 
normalization of hypokalemia (if present presurgically; biochemi-
cal outcomes).10 PA was diagnosed by the US Endocrine Society 
guideline or the Japan Endocrine Society guideline.6,29 All details on 
patient inclusion and assessment are provided in the online-only Data 
Supplement. The study was approved by an institutional review board 
with patient data and written informed patient consent obtained in 
accordance with local ethical guidelines.
Statistical Analyses
Data are expressed as absolute numbers and percentages, means 
with SD, or as medians with interquartile ranges as appropriate. IBM 
SPSS statistics version 22.0 was used for all analyses. P values <0.05 
were considered significant. Details of all statistics are given in the 
online-only Data Supplement.
Results
An expanded Results section is available in the online-only 
Data Supplement.
Figure 1. Clinical and biochemical outcomes 
of patients stratified by surgical management 
decision. Outcomes were assessed in 
accordance with the PASO (Primary 
Aldosteronism Surgical Outcome) consensus 
and are shown as proportions of patients (%) 
with absolute numbers in parenthesis for each 
clinical or biochemical outcome category 
(complete, partial, or absent). A total of 233 
and 235 patients had clinical and biochemical 
outcome data, respectively in the computed 
tomography (CT) group and 526 patients had 
both clinical and biochemical outcome data 
in the adrenal venous sampling (AVS) group. 
*P<0.001.
3Table 1. Clinical Variables of Patients Stratified by CT- or AVS-Based Management
Variable N Total
Surgical Management
P ValueCT AVS
Clinical outcome (N=759) Complete 286 (37.7) 90 (38.6) 196 (37.3) 0.718
Partial 363 (47.8) 113 (48.5) 250 (47.5) 0.806
Absent 110 (14.5) 30 (12.9) 80 (15.2) 0.399
Biochemical outcome (N=761) Complete 679 (89.2) 188 (80.0) 491 (93.3) <0.001
Partial 43 (5.7) 18 (7.7) 25 (4.8) 0.109
Absent 39 (5.1) 29 (12.3) 10 (1.9) <0.001
Age at surgery, y 761 50.4±11.1 49.3±11.3 50.9±11.0 0.068
Sex (female), % 761 377 (49.5) 132 (56.2) 245 (46.6) 0.014
BMI, kg/m2 761 27.1±4.9 27.2±4.4 27.1±5.1 0.742
Baseline parameters
 Aldosterone, pmol/L 760 895.0 (590.9–1445.3) 923.7 (635.2–1481.3) 876.6 (569.4–1439.7) 0.056
 PRA, pmol/L per minute 460 2.6 (1.3–5.1) 2.6 (2.6–4.4) 2.6 (1.3–5.1) 0.782
 ARR_PRA 460 367.8 (170.2–748.7) 419.4 (217.0–835.9) 363.3 (158.3–708.7) 0.072
 DRC, mU/L 301 4.0 (2.5–7.9) 2.5 (2.5–3.8) 4.9 (3.2–10.1) <0.001
 ARR_DRC 301 199.8 (91.6–324.6) 264.1 (181.4–381.4) 153.6 (60.2–297.2) <0.001
 Lowest serum potassium, mmol/L 760 3.1±0.6 3.2±0.7 3.1±0.6 0.051
 Systolic BP, mm Hg 760 154±21.4 159±18.8 152±22.2 <0.001
 Diastolic BP, mm Hg 759 95±13.4 99±11.9 93±13.6 <0.001
 Antihypertensive medication (DDD) 758 2.7 (1.5–4.5) 2.7 (1.7–4.3) 2.7 (1.5–4.5) 0.800
 Diabetes mellitus (yes), % 760 107 (14.1) 29 (12.4) 78 (14.8) 0.373
 eGFR, mL/min per m2 714 87±23.1 94±24.5 84±22.0 <0.001
 Twenty-four hours albuminuria, mg/d 545 15.0 (9.9–50.0) 15.0 (10.0–62.8) 15.0 (9.0–49.3) 0.693
 LVH-echocardiography (yes), % 615 316 (51.4) 88 (48.4) 228 (52.7) 0.330
 Largest nodule at imaging (diameter), mm 761 14 (10.0–19.0) 16 (11.0–22.0) 13 (8.8–17.0) <0.001
Follow-up parameters
 Aldosterone, pmol/L 760 241.3 (140.4–357.6) 273.3 (141.5–438.3) 238.6 (140.0–338.4) 0.020
 PRA, pmol/L per minute 439 15.4 (6.4–30.7) 11.7 (5.7–25.6) 19.2 (6.9–38.4) 0.001
 ARR_PRA 439 14.0 (5.9–33.6) 15.1 (7.8–45.1) 13.2 (5.4–31.0) 0.021
 DRC, mU/L 319 18.8 (9.3–30.8) 11.2 (7.2–21.9) 22.4 (11.0–36.2) <0.001
 ARR_DRC 319 13.3 (5.7–26.4) 28.1 (16.6–42.9) 9.4 (4.5–18.7) <0.001
 Lowest serum potassium, mmol/L 760 4.4±0.5 4.3±0.5 4.4±0.4 0.356
 Systolic BP, mm Hg 761 130±14.2 133±13.8 129±14.3 <0.001
 Diastolic BP, mm Hg 761 82±9.9 83±8.9 81±10.3 0.013
 Antihypertensive medication (DDD) 761 0.7 (0.0–2.0) 1.0 (0.0–2.0) 0.5 (0.0–2.3) 0.817
Postoperative change (baseline−follow-up)
 ΔSystolic BP, mm Hg 760 24±21.2 26±18.3 23±22.4 0.140
 ΔDiastolic BP, mm Hg 759 13±13.7 16±12.3 11±14.2 <0.001
 ΔDDD 758 1.5 (0.5–3.0) 1.5 (0.7–2.5) 1.5 (0.5–3.0) 0.508
The Δ postoperative changes are calculated as baseline−follow-up as indicated. A positive value indicates a decrease and a negative value indicates an increase. 
ARR indicates aldosterone-to-renin ratio; ARR_DRC, ARR calculated using direct renin concentration; ARR_PRA, ARR calculated using PRA; AVS, adrenal venous 
sampling; BMI, body mass index; BP, blood pressure; CT, computed tomography; DDD, defined daily dose (assumed average maintenance dose per day for a drug used 
for its main indication in adults [https://www.whocc.no/atc_ddd_index/]); DRC, direct renin concentration; eGFR, estimated glomerular filtration rate; LVH, left ventricular 
hypertrophy; and PRA, plasma renin activity.
4Biochemical Outcomes Stratified by CT- and AVS-
Based Surgical Decision
The CT group comprised a smaller proportion of patients 
achieving complete biochemical success after surgery (cure 
of PA; 188 of 235 patients, 80.0%) compared with AVS (491 
of 526, 93.3%; P<0.001) and a higher proportion with absent 
biochemical success (12.3% versus 1.9%, P<0.001) and per-
sisting PA (partial and absent biochemical success combined; 
20.0% versus 6.7%, P<0.001; Figure 1; Table 1). Similar 
clinical and biochemical outcomes were observed when the 
analysis was restricted to centers using either an AVS or CT 
scan approach (Figure S2).
Clinical Outcomes Stratified by CT- and AVS-Based 
Surgical Decision
The proportion of patients achieving complete clinical suc-
cess was similar (38.6% versus 37.3% in the CT and AVS 
groups, respectively, P=0.718; Figure 1; Table 1). Despite 
this, in the CT group, the median postsurgical ARR (mea-
sured with plasma renin activity because direct renin con-
centration measurements may perform less well compared 
with plasma renin activity for low renin values)30,31 was 
highly elevated in patients with an absent clinical out-
come (107.1, interquartile range, 64.5–213.5; Table S2) 
and significantly greater than in patients with either partial 
(P<0.001) or complete clinical success (P<0.001; Figure 2; 
Table S2). Patients with AVS management displayed no sig-
nificant differences in the ARR stratified for clinical out-
comes (Figure 2; Table S4).
Assessment of postsurgical outcomes across centers indi-
cated less variance in clinical remission (22% to 48%) and a 
wider variance in biochemical remission (67% to 92%) with 
CT management relative to that noted previously with AVS 
(Figure S2).10 There was no discernable timeline bias for the 
diagnosis of the patients with absent or partial biochemical 
success with CT surgical management (Figure S1) and these 
patients were not concentrated in any particular center (Figure 
S3).
Identification of Factors Associated With CT- and 
AVS-Based Surgical Outcomes
Patient characteristics were stratified for clinical and bio-
chemical outcomes based on CT- (Tables S2 and S3) or AVS-
based management (Tables S4 and S5). In agreement with the 
PASO study, the unadjusted analysis showed that younger 
age, female sex, lower body mass index, and an absence of 
target organ damage to kidneys and heart were factors associ-
ated with complete clinical success in the AVS group (Table 
S4). Three of these (younger age, female sex, and lower body 
mass index) were also associated with complete clinical suc-
cess in the CT group (Table S2).
A CT-based surgical decision was a factor associated with 
a lower likelihood of complete biochemical success com-
pared with an AVS-based surgical decision (complete versus 
partial+absent: adjusted odds ratio [OR], 0.28; 0.16–0.50; 
P<0.001). The approach to surgical management did not influ-
ence the likelihood of clinical outcomes (Table 2).
In the total cohort, the absence of an elevated ARR at 
follow-up was a factor associated with both complete clinical 
success (adjusted OR, 4.92; 1.63–14.88; P=0.005) and clinical 
benefit (complete+partial clinical success combined: adjusted 
OR, 7.46; 3.35–16.63; P<0.001; Table 2). This marker of 
clinical outcome was driven by patients with CT manage-
ment where the absence of an elevated postsurgical ARR 
was associated with complete clinical outcome (adjusted OR, 
14.81; 1.76–124.53; P=0.013) and clinical benefit (adjusted 
OR, 45.49; 11.63–177.93; P<0.001). The ARR at follow-up 
was not associated with clinical outcome in the AVS group 
(Table 2).
Reliability of CT Compared With AVS for the 
Diagnosis of Unilateral PA Including Young Patients 
<35 Years of Age
In the diagnostic workup of PA, CT scanning precedes 
AVS to exclude the presence of adrenocortical carcinoma. 
Comparison of CT with AVS results showed discordant find-
ings in 178 (36% of 491) patients with AVS management 
(who were biochemically cured after adrenalectomy). If CT 
data had been used for subtype differentiation, resection of 
the wrong adrenal would have occurred in 9 patients (2%) and 
169 patients (34%) would have missed the chance of surgery 
because of an inappropriate diagnosis of bilateral disease (71 
patients [14%] with bilateral normal and 98 patients [20%] 
with bilateral abnormal adrenals; Figure 3A).
We tested the reliability of CT management in young 
patients (<35 years) with specific biochemical (baseline 
plasma aldosterone concentration >30 ng/dL and spontane-
ous hypokalemia) and imaging characteristics. There were 40 
Figure 2. Stratification of the postsurgical aldosterone-to-renin ratio 
(ARR) by clinical outcomes and surgical management decision. The box 
and whisker plot shows the median aldosterone-to-renin ratio at follow-
up (thick horizontal line within bars) derived from plasma renin activities 
stratified for clinical outcomes (C, complete; P, partial; and A, absent 
clinical success) in the computed tomography (CT) and adrenal venous 
sampling (AVS) groups. The analysis included data from 136 patients in 
the CT group (complete [n=55], partial [n=61], and absent [n=20] success) 
and from 303 patients in the AVS group (complete [n=126], partial [n=147], 
and absent [n=30] success). ARR assessed using the plasma renin activity. 
*P<0.001 vs partial vs complete success in the CT group.
5Table 2. Clinical Variables Associated With Outcomes Stratified by CT- or AVS-Based Management Decision
Variables
Clinical Outcome Biochemical Outcome
OR (95% CI) P Value OR (95% CI) P Value
CT group: complete vs partial+absent (reference: complete)
 Age, per y 0.96 (0.92–0.99) 0.024 0.99 (0.95–1.03) 0.652
 Lowest serum potassium, per mmol/L 1.39 (0.70–2.78) 0.347 2.27 (1.11–4.76) 0.024
 BMI, per 1 kg/m2 0.99 (0.91–1.08) 0.850 0.87 (0.79–0.96) 0.007
 eGFR, per mL/min per 1.73 m2 1.01 (0.99–1.02) 0.687 0.99 (0.98–1.01) 0.607
 Sex (ref: female) 4.37 (2.02–9.46) <0.001 1.06 (0.47–2.39) 0.887
 LVH (ref: not detected) 2.38 (1.12–5.06) 0.025 1.93 (0.87–4.30) 0.108
 Elevated ARR at FU (ref: not detected) 14.81 (1.76–124.53) 0.013 NA NA
CT group: complete+partial vs absent (reference: complete+partial)
 Age, per y 1.04 (0.98–1.11) 0.216 1.00 (0.95–1.05) 0.989
 Lowest serum potassium, per mmol/L 1.61 (0.57–4.55) 0.370 3.23 (1.28–8.32) 0.013
 BMI, per 1 kg/m2 0.95 (0.81–1.12) 0.489 0.88 (0.78–0.99) 0.044
 eGFR, per mL/min per 1.73 m2 1.01 (0.98–1.03) 0.698 0.99 (0.98–1.02) 0.709
 Sex (ref: female) 0.88 (0.24–3.18) 0.843 1.44 (0.52–3.99) 0.483
 LVH (ref: not detected) 1.00 (0.28–3.60) 0.994 1.43 (0.53–3.82) 0.480
 Elevated ARR at FU (ref: not detected) 45.49 (11.63–177.93) <0.001 NA NA
AVS group: complete vs partial+absent (reference: complete)
 Age, per y 0.95 (0.93–0.98) <0.001 0.98 (0.94–1.02) 0.392
 Lowest serum potassium, per mmol/L 1.27 (0.85–1.85) 0.249 1.52 (0.75–3.03) 0.247
 BMI, per 1 kg/m2 0.96 (0.92–1.01) 0.097 0.96 (0.89–1.03) 0.218
 eGFR, per mL/min per 1.73 m2 1.01 (1.00–1.02) 0.071 0.99 (0.97–1.01) 0.330
 Sex (ref: female) 2.48 (1.57–3.93) <0.001 0.93 (0.41–2.14) 0.873
 LVH (ref: not detected) 1.98 (1.26–3.11) 0.003 0.63 (0.28–1.43) 0.269
 Elevated ARR at FU (ref: not detected) 2.55 (0.68–9.59) 0.166 NA NA
 Basis for surgery decision (ref: CT scan) NA NA NA NA
AVS group: complete+partial vs absent (reference: complete+partial)
 Age, per y 0.96 (0.93–0.99) 0.013 1.03 (0.96–1.11) 0.383
 Lowest serum potassium, per mmol/L 1.30 (0.79–2.17) 0.305 0.97 (0.30–3.13) 0.956
 BMI, per 1 kg/m2 0.94 (0.89–0.99) 0.016 0.89 (0.80–0.99) 0.038
 eGFR, per mL/min per 1.73 m2 1.01 (0.99–1.02) 0.427 1.02 (0.98–1.05) 0.352
 Sex (ref: female) 2.15 (1.15–4.01) 0.016 1.76 (0.40–7.75) 0.455
 LVH (ref: not detected) 0.95 (0.54–1.69) 0.864 0.62 (0.16–2.49) 0.501
 Elevated ARR at FU (ref: not detected) 1.47 (0.39–5.58) 0.573 NA NA
 Basis for Surgery Decision (ref: CT scan) NA NA NA NA
AVS+CT group: complete vs partial+absent (reference: complete)
 Age, per y 0.96 (0.94–0.97) <0.001 0.99 (0.96–1.02) 0.400
 Lowest serum potassium, per mmol/L 1.28 (0.91–1.79) 0.157 1.82 (1.11–3.03) 0.018
 BMI, per 1 kg/m2 0.97 (0.93–1.01) 0.076 0.93 (0.88–0.98) 0.007
 eGFR, per mL/min per 1.73 m2 1.01 (0.99–1.02) 0.100 0.99 (0.98–1.01) 0.345
 Sex (ref: female) 2.90 (1.96–4.27) <0.001 0.96 (0.55–1.69) 0.898
 LVH (ref: not detected) 1.99 (1.36–2.91) <0.001 1.12 (0.64–1.95) 0.686
 Elevated ARR at FU (ref: not detected) 4.92 (1.63–14.88) 0.005 NA NA
 Basis for surgery decision (ref: CT scan) 1.04 (0.67–1.60) 0.859 0.28 (0.16–0.50) <0.001
(Continued )
6(7.6% of 526) and 20 (8.5% of 235) patients aged <35 years 
of age in the AVS and CT groups, respectively. The CT results 
indicated that 26 of the patients in the AVS group (65% of 
40, all with complete biochemical success) and 11 in the CT 
group (55% of 20 patients, 8 complete, 1 partial, and 2 absent 
biochemical success) had a unilateral adrenal mass (>10 mm 
diameter) with a normal appearing contralateral adrenal. 
These imaging results combined with a marked phenotype of 
PA at baseline (plasma aldosterone concentration >30 ng/dL 
and spontaneous hypokalemia) were observed in 17 (12 com-
plete and 5 partial clinical success) and 5 (2 complete, 2 par-
tial clinical success, and 1 with missing clinical data) patients 
aged <35 years, all of whom were biochemically cured by 
adrenalectomy.
Discussion
The diagnosis of unilateral PA by AVS and treatment by total 
unilateral adrenalectomy results in biochemical remission 
in >9 out of 10 patients and clinical remission or a marked 
improvement in clinical parameters in >4 out of 5 patients.10 
An outcome of partial or absent biochemical success after 
surgery defines those patients with persisting hyperaldoste-
ronism and therefore presumably bilateral PA that was mis-
diagnosed as unilateral preoperatively. The accurate diagnosis 
of unilateral PA that determines the therapeutic strategy is 
thus fundamental if a patient is to be offered the possibility of 
biochemical cure.
Herein, we show that the likelihood of cure of aldoste-
ronism (complete biochemical success) with AVS-based 
surgical management is higher relative to surgery based on 
adrenal CT. Although this was not accompanied by a higher 
likelihood of clinical cure, it is noteworthy that evidence of 
persisting PA (indicated by an elevated ARR which is a cri-
terion of absent and partial biochemical success) in patients 
with a CT-based diagnosis was associated with unfavorable 
clinical outcomes (absent in patients with AVS management). 
Furthermore, it is well established that long-term excessive 
and autonomous aldosterone production leads to severe detri-
mental effects independent of blood pressure control and car-
ries an increased risk of cardiovascular and cardiometabolic 
events and death relative to patients with primary hyperten-
sion.5,11–16 Additionally, the persistence of low plasma renin 
activity levels in patients with PA treated with mineralocor-
ticoid receptor antagonists (indicating persistence of inap-
propriate activation of the mineralocorticoid receptor by 
aldosterone) is associated with unfavorable cardiovascular 
long-term outcomes.16 These observations highlight the clini-
cal importance of biochemical (and not just clinical) cure and 
support the recommendation of long-term yearly follow-up 
with both clinical and biochemical assessment in adrenalec-
tomized patients with PA.10,16 Herein, we report that in the 
group with an AVS-based surgical decision, the ARR was not 
elevated in patients with absent clinical outcomes indicating 
that other factors likely determined the lack of clinical remis-
sion such as preexisting primary hypertension, long duration 
of hypertension, older age, and renal insufficiency. In con-
trast, with CT management, persistent hyperaldosteronism 
was a potential additional factor that contributed to absent 
clinical outcomes indicated by the elevated ARR.
The main differences between our study and that of 
Dekkers et al,28 other than the retrospective observational 
versus prospective randomized design, was the assessment 
of outcomes in accordance with a standardized set of crite-
ria10 and the greater number of patients with unilateral PA 
included in the present study (235 and 526 patients in the CT 
and AVS groups, respectively) compared with the prospective 
study (46 patients in each group). Despite these differences, 
the proportions of patients with complete biochemical suc-
cess reported in both are highly similar (80% with a diagnosis 
by CT in both studies and 93% versus 89%, in this and in 
Dekkers’ study, diagnosed by AVS). These observations raise 
the possibility that with sufficient numbers the prospective 
AVS+CT group: complete+partial vs absent (reference: complete+partial)
 Age, per y 0.98 (0.95–1.01) 0.087 1.01 (0.97–1.05) 0.554
 Lowest serum potassium, per mmol/L 1.43 (0.92–2.22) 0.114 2.04 (1.02–4.17) 0.044
 BMI, per 1 kg/m2 0.93 (0.89–0.98) 0.005 0.88 (0.82–0.95) 0.002
 eGFR, per mL/min per 1.73 m2 1.01 (0.99–1.02) 0.319 1.01 (0.99–1.02) 0.747
 Sex (ref: female) 1.81 (1.07–3.09) 0.028 1.50 (0.66–3.40) 0.327
 LVH (ref: not detected) 0.94 (0.57.1.55) 0.802 1.01 (0.46–2.20) 0.999
 Elevated ARR at FU (ref: not detected) 7.46 (3.35–16.63) <0.001 NA NA
 Basis for surgery decision (ref: CT scan) 1.85 (0.99–3.45) 0.053 0.15 (0.06–0.36) <0.001
Logistic regressions identified factors associated with complete clinical and biochemical success. An odds ratio >1 shows an increased odds (or likelihood) of 
clinical or biochemical outcome, whereas an odds ratio of <1 means that the odds for the indicated outcome are decreased. The odds ratios for serum potassium 
were calculated for lowest values, and therefore an odds ratio >1 indicates a decreased odds and an odds ratio <1 means that the odds are increased. ARR indicates 
aldosterone-to-renin ratio; ARR at FU, aldosterone-to-renin ratio at follow-up (an elevated ARR was calculated by ARR_PRA >65 or ARR_DRC >102.6, with aldosterone 
in pmol/L, PRA in pmol/L/min and DRC mU/L); AVS, adrenal venous sampling; BMI, body mass index; CI, confidence interval; CT, computed tomography; eGFR, estimated 
glomerular filtration rate; FU, follow-up; LVH, left ventricular hypertrophy; NA, not applicable: an elevated ARR is a criterion of partial and absent biochemical success; 
OR, odds ratio; and ref, reference.
Table 2. Continued
Variables
Clinical Outcome Biochemical Outcome
OR (95% CI) P Value OR (95% CI) P Value
7study would also have demonstrated significant differences in 
surgical outcomes between the CT- and AVS-based treatment 
groups, as acknowledged by Dekkers et al.28
We demonstrate the lower performance of nonfunctional 
imaging compared with AVS for the diagnosis of lateralized 
aldosterone excess in unilateral PA. The high level of discor-
dance between imaging and AVS results for determining lat-
eralization in PA has been reported previously.25,32 The present 
study is, however, the largest cohort to date that uses uniform 
(albeit post hoc) follow-up data assessed in accordance with 
an international consensus.10 Our data also support the concept 
that adrenal CT may tend to miss smaller adenomas because 
the median size of the adenomas detected in the CT group was 
significantly larger than in the AVS group (determined by CT 
scanning).
In patients with confirmed unilateral PA (on the basis of 
biochemical cure at follow-up) imaging data alone would 
result in 1 in every 50 patients undergoing the removal of the 
wrong adrenal and 1 in every 3 patients missing the chance of 
surgery and the possibility of a cure (by being misdiagnosed 
as bilateral normal or bilateral abnormal). A higher number 
of misdiagnoses could result if patients <35 years of age 
are excluded. The overall discordance between CT and AVS 
results we report is highly similar to that of a systematic review 
(36% versus 38%) albeit the incidence of potential adrenalec-
tomies on the wrong side in our study is lower (2% versus 
4%), a difference that may be accounted for by the availability 
of follow-up data in all patients in our study and the inclusion 
of only patients with confirmed PA.25 Despite the high level of 
discordance, we show in a cohort of 60 young patients (aged 
Figure 3. Reliability of computed tomography 
(CT) compared with adrenal venous sampling 
(AVS) for the diagnosis of unilateral primary 
aldosteronism. A comparison of CT with AVS 
results in patients with AVS management who 
were biochemically cured after adrenalectomy 
(491 of 526 patients) indicated discordant 
findings in 36% of patients (A); there were 
40 and 20 patients aged <35 years of age in 
the AVS and CT groups, respectively. The CT 
results indicated that 26 and 11 patients in the 
AVS and CT groups had a unilateral adrenal 
mass (>10 mm diameter), respectively, with 
a normal appearing contralateral adrenal. A 
marked phenotype of primary aldosteronism 
(PA) at baseline (plasma aldosterone 
concentration >30 ng/dL and spontaneous 
hypokalemia) was observed in 17 (12 complete 
and 5 partial clinical success) and 5 (2 
complete, 2 partial clinical success, and 1 
with missing clinical data) of these patients, 
all of whom were biochemically cured by 
adrenalectomy (B).
8<35 years) that CT scanning combined with predictors based 
on young age and phenotype is a reliable approach to bypass 
AVS as recommended by the ES guideline6 and in agreement 
with a study performed in Japan.33
Limitations include the retrospective design and the 
potential for selection bias, the use of criteria for lateralization 
by CT that was not rigidly defined and office blood pressure 
measurements that were standard practice during much of the 
study period of patient evaluation. This may help to explain 
why the major differences between the CT and AVS cohorts 
reported herein were not defined by blood pressure measure-
ments but by biochemical parameters.
The strengths of our study are the large cohort with 
patient follow-up data from diverse international centers 
with outcomes assessed in accordance with an interna-
tionally recognized set of criteria developed by a group of 
experts in the field.
Perspectives
Compared with AVS, a diagnosis of unilateral PA by CT 
results in similar clinical outcomes (blood pressure and anti-
hypertensive medication) but decreases the likelihood of bio-
chemical cure after treatment by adrenalectomy. Based on our 
data, CT-based decision-making is a valid strategy in young 
patients with PA with a marked phenotype, but otherwise, 
AVS should be considered the preferred method to differen-
tiate unilateral from bilateral PA. Notwithstanding, it should 
be acknowledged that AVS is a challenging and nonstandard-
ized technique that is not available at all centers. However, 
the correct diagnosis and treatment of patients with unilateral 
forms offer a potential cure and the possibility to avoid comor-
bidities associated with long-term inappropriate aldosterone 
production.
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What Is New?
• We assessed outcomes of 761 patients treated by total unilateral adre-
nalectomy for unilateral primary aldosteronism with a surgical approach 
based on computed tomography (CT) or adrenal venous sampling.
• CT-based management was more likely to be associated with inappro-
priate postsurgical aldosterone production in patients with absent clinical 
success.
• A diagnosis by CT was associated with a decreased likelihood of com-
plete biochemical success compared with adrenal venous sampling.
What Is Relevant?
• CT-based management predicts a decreased likelihood of biochemical
cure of unilateral primary aldosteronism after surgery compared with
adrenal venous sampling.
Summary
Patients with a diagnosis of unilateral primary aldosteronism by CT 
scanning have unfavorable biochemical outcomes compared with 
a diagnosis by adrenal venous sampling.
Novelty and Significance
